Objective: Roux-en-Y gastric bypass surgery (RYGB) improves the first phase of glucose-stimulated insulin secretion (GSIS) in patients with type 2 diabetes. How it does so remains unclear. Farnesoid X receptor (FXR), the nuclear receptor of bile acids (BAs), is implicated in bariatric surgery.
INTRODUCTION
The prevalence of type 2 diabetes (T2D) originates from b-cell failure to compensate insulin resistance and secrete the necessary amount of insulin to maintain glucose homeostasis [1] . RYGB has been recognized the choice for treatment of T2D patients because it leads to normalization of hyperglycemia within days after surgery, an effect is thought independent of weight loss [2, 3] . How it does so remain unclear, although an improved secretory capacity of pancreatic b-cells has been postulated [4] . Particularly, the first phase of GSIS, which is severely impaired in T2D, has been restored shortly after RGYB in T2D patients [4, 5] and animal models [6] . The first phase of GSIS is attributable to ATP-driven closure of ATPsensitive potassium channels (K ATP ), depolarization of the plasma membrane, and opening of the voltage-gated Ca 2þ channels with subsequent increase in cytoplasmic Ca 2þ concentration. Importantly, this process requires an additional small inward current that can bring the membrane potential away from the equilibrium potential of K þ , which results in initiation of action potential firing and insulin secretion [7, 8] . The transient receptor potential (TRP) channels have been hypothesized to be responsible for this inward cation current [9, 10] . As a member of the transient receptor potential (TRP) channel superfamily, TRP ankyrin 1 (TRPA1) is abundantly expressed in pancreatic b-cells, but not a-cells [11] . TRPA1 is a Ca 2þ permeable non-selective cation channel that responds to noxious cold, divalent cations and polyunsaturated fatty acids [12] . Activation of TRPA1 by its agonist induces inward current, which leads to membrane depolarization and Ca 2þ 1 influx and potentiates insulin secretion [11, 13] . Although these pharmacological data suggest that TRPA1 may be involved in stimulussecretion coupling in b-cells, the physiological significance of this channel in b-cell function remains to be confirmed in TRPA1-deficient mice. Furthermore, the alterations of TRPA1 in b-cells in diabetes, particularly its association with impaired GSIS have not been explored. RYGB leads to elevation of serum bile acids (BAs) in T2D patients [14] and diabetic rats [15] . As an important metabolic regulator, BA signaling plays a critical role in improved glucose homeostasis and remission of diabetes after RYGB [3, 16] . Emerging evidences demonstrate that BAs enhance GSIS, an effect that is attributed to activation of its nuclear farnesoid X receptor (FXR) [17, 18] , since BAs fail to potentiate GSIS in FXR À/-islets [18] . FXR, a ligand-activated transcription factor belonging to the nuclear receptor superfamily [19] , has been identified in human and rodent b-cells [17, 18] . Activation of FXR by BAs or FXR agonist GW4064 potentiates GSIS [17, 18] .
However, the precise mechanism by which this is achieved remains largely unknown. In this study, we found that RYGB restores TRPA1 expression in b-cells from diabetic GK rats, via increasing BAs with subsequent stimulating FXR-mediated recruitment of histone acetyltransferase steroid receptor coactivator-1 (SRC1), and promoting the acetylation of histone H3 (ACH3) at the promoter of TRPA1. We also demonstrate that TRPA1 is required for the ability of glucose to evoke electrical activity and stimulate insulin secretion in b-cells. Thus, increased TRPA1 in b-cells would account for improved GSIS and glycemic control in diabetes after RYGB.
MATERIALS AND METHODS

Experimental animals
Male Wistar and GK rats aged 10 wk were purchased from SLRC Laboratory Animal company (Shanghai, China). FXR knockout mice (C57Bl/6) were kindly provided by Prof. Youfei Guan at Dalian University, China [20] . TRPA1 knockout mice (C57BL/6J) were purchased from The Jackson Laboratory (Bar Harbor, USA). All animals were maintained on a normal diet and kept in the conventional vivarium with a 12-h day/night cycle (lights on at 7:00 and off at 19:00). The animals were housed at room temperature (22e25 C) and were allowed to adapt to the new environment for 1 wk before the surgery. GK rats were randomized to RYGB or sham operation. Male FXR or TRPA1 transgenic mice aged 18e20 wk with body weight >25 g were used for RYGB or sham operation. Survival rates after surgery were 100% for RYGB and sham GK rats; and 75% for RYGB mice and 100% for sham mice. The animal procedures were performed according to the Principles of Laboratory Animal Care and approved by the Shenzhen University Animal Care Committee.
RYGB on GK rats
The RYGB procedure was performed as described previously [6] . Rats were fasted overnight and anesthetized with isoflurane (3% for induction, 2% for maintenance). Under sterile conditions, a midline laparotomy was performed. The stomach was divided into two by a suture along the white line between the forestomach and glandular stomach. A biliopancreatic limb extending 16 cm from the ligament of Treitz was transected. The distal segment was anastomosed to the gastric remnant, and the proximal segment was drained into 30 cm of the Roux limb by side-to-side anastomosis. For the GK-PF-shamoperated animals, following laparotomy, an incision was made at a spot 16 cm from the ligament of Treitz. The intestine was then reconnected by side-to-side anastomosis, without intestinal rearrangement, and the incision was closed.
RYGB on FXR or TRPA1 transgenic mice
The RYGB procedure was conducted using a modification of the approach described by Nestoridi et al. [21] . The stomach was ligated between the glandular portion and the gastric fundus (forestomach). The jejunum was transected at 4 cm from the ligament of Treitz and 6 cm from the site of gastroenterostomy. The distal segment of jejunum was anastomosed to the forestomach. The sham procedure involved mobilization of the forestomach and proximal and distal jejunum and ileum without any transection. After surgery, animals were left to recover in a warm box and then returned to the animal facility. They were injected with buprenorphine and ampicillin for 3 days. All surgical GK rats were given purified water for 12 h before started on the normal chow; whereas the surgical mice were maintained on a liquid diet (Novartis, NY) for 10 days until weaned back to solid normal chow.
Intravenous glucose tolerance test
Rats were fasted overnight and anesthetized with isoflurane. The rats were given glucose at a dose of 1 g/kg through a jugular vein catheter. Blood samples were then collected at 0, 2, 5, 10, and 30 min after glucose administration to measure insulin. or acetylated histone 3 (#06e599, Millipore) or SRC1 (#ab2859, Abcam, Cambridge, MA), respectively. DNA extractions were sequenced from À1717 bp to À1605 bp in TRPA1 promoter by using the primers listed in Supplemental Table 2. 2.11. Construction of TRPA1-Luc plasmid and promoter reporter assay Rat TRPA1 promoter fragment between À1979 bp and À59 bp was amplified by PCR using the primers listed in Supplemental Table 3 and cloned into pGL3-basic luciferase reporter vector (Promega, Madison, WI). Site-directed mutagenesis of the putative FXR binding site from À1657bp to À1655bp was accomplished using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technology, Santa Clara, CA) by using the mutagenic primers listed in Supplemental Table 3 . 293 T cells were transfected with TRPA1-Luc plasmid and Renilla luciferase plasmid, followed by stimulation with 5 mM GW4064 for 24 h. TRPA1 promoter activity was determined by using the Dual-Luciferase Reporter Assay kit (Promega) according to the manufacturer's instructions. The plasmid expressing Renilla luciferase was used for normalization of luciferase activity.
2.12. RNA purification and real time PCR Total RNA was extracted from INS-1 832/13 cells or islets using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Real time PCR was performed using qTOWER 2.2 real time PCR System (Germany). The primer sequences are listed in Supplemental Table 4 . TRPA1 expression was normalized to GAPDH or b-actin.
Insulin measurements
Insulin secretion was assayed as described previously [22] .
2.14. Statistical analyses Data are presented as mean AE S.E.M. for the indicated number of experiments (n). Statistical significance was evaluated using the independent t-test or One-way ANOVA. Data were considered significant when p < 0.05. Figure 1A) , consistent with the previous observations [6] . In accordance with these findings in vivo, treatment of GK-RYGB islets with 16.8 mM glucose for 10 min led to a w7-fold increase of insulin secretion (p < 0.05), in contrast to only a w1.4-fold stimulation in GK-sham islets ( Figure 1B ). This was paralleled by improved glycemic controls ( Figure 1C ) and a sustained reduction in glucose levels ( Figure 1D ) in GK-RYGB rats, consistent with remission of diabetes. Note that there was no significant difference of the body weights between GK-RYGB and GKsham groups (Supplemental Fig. 1 ), as reported previously [6] .
RESULTS
RYGB improves GSIS and reverses hyperglycemia in GK rats
RYGB restores TRPA1 expression and current in GK b-cells
Analysis of TRPA1 expression revealed that GK-sham islets had w47% (p < 0.01) and w46% (p < 0.01) lower TRPA1 mRNA and protein levels, respectively, than the Wistar controls (Figure 2A, B) . Notably, RYGB led to an increase of TRPA1 expression: GK-RYGB islets had w34% (p < 0.01) and w39% (p < 0.01) higher in TRPA1 mRNA and protein levels, respectively, than the sham controls (Figure 2A, B) . The increase in TRPA1 expression was consistent with an enhanced TRPA1 current recorded in single b-cells from these rats (RYGB vs.
sham, À5.25 AE 0.8 pA/pF vs. À2.29 AE 0.37 pA/pF, p < 0.01) (Figure 2CeF ), albeit still lesser than the value of Wistar controls (À8.91 AE 1.36 pA/pF) ( Figure 2C , E and F). We next examined whether the observed reduction of TRPA1 in GK rats was due to hyperglycemia. We conducted the experiments by culturing INS-1 832/13 cells in 5.5 mM glucose (G5.5) or 30 mM glucose (G30) medium for 3 days. Western blotting revealed that TRPA1 protein levels were similar in the two groups (Supplemental Fig. 2 ). Thus, reduced TRPA1 expression in GK rats is not attributed to extracellular high glucose levels. Original Article
To explore whether TRPA1 is involved in RYGB-potentiated GSIS, we performed RYGB and sham surgeries on TRPA1 þ/þ and TRPA1
À/À mice, and determined GSIS in islets isolated from these mice ( Figure 3A ) or IVGTT in vivo ( Figure 3B ). Thus, treatment with 16.8 mM glucose for 10 min led to a w3.4-fold increase of insulin secretion as compared to 2.8 mM glucose in TRPA1 þ/þ sham islets, in contrast to w1.8-fold increase in TRPA1 À/À sham islets ( Figure 3A) . Importantly, glucose stimulation produced a further w80% greater (p < 0.01) of insulin secretion in TRPA1 þ/þ RYGB islets, but not in TRPA1 À/À RYGB islets ( Figure 3A ). In agreement with the observation made in islets, IVGTT results revealed that TRPA1 þ/þ RYGB mice displayed a marked increase (p < 0.01) of GSIS than sham controls, especially insulin secretion at 2 min after glucose administration ( Figure 3B ). Strikingly, however, TRPA1
À/À RYGB mice responded with an attenuated increase (w2.5-fold lower peak; p < 0.01) in insulin levels ( Figure 3B ). This was paralleled by a diminished effect of RYGB on glucose control in TRPA1 À/À mice ( Figure 3C ). Notably, GSIS assayed either in islets (Supplemental Fig. 3 ) or IVGTT (Supplemental Fig. 4 ) in vivo was comparable between sham and non-surgery groups, suggesting that surgery did not affect secretory capacity of b-cells in these TRPA1 mice. These findings prompted us to investigate the role of TRPA1 in b-cell electrical activity and insulin secretion, by analyzing the b-cell electrophysiological properties and insulin secretion in TRPA1 þ/þ and TRPA1 À/À mice. As shown in Figure 4A , B, exposure to 2.8 mM glucose, TRPA1
À/À b-cells had a more hyperpolarized membrane
vs. À70.2 AE 0.9 mV (n ¼ 25), p < 0.001). Upon stimulation with 16.8 mM glucose, TRPA1
1.24 AE 0.31 Hz (n ¼ 25), p < 0.01), as well as a lesser extent of GSIS (w2-fold vs. w3.6-fold increase in TRPA1 À/À and TRPA1 þ/þ islets, respectively; p < 0.01) ( Figure 4C ). This is consistent with an attenuated increase of GSIS in TRPA1 À/À mice in vivo ( Figure 4D ).
Moreover, we confirmed that, as previously reported [11] , TRPA1 agonist AITC stimulated whereas its antagonist HC-030031 suppressed glucose-elicited firing ( Figure 4E , F) and GSIS ( Figure 4G , H) in b-cells from normal Wistar rats.
Lack of RYGB-induced TRPA1 expression in islets from FXR
À/-mice It has been reported that RYGB causes significant increase in BA levels in Zucker diabetic rats [15] . We determined whether RYGB surgery also exerts similar effects on BA levels in non-obese GK rats. Plasma BA levels were assessed in GK rats 2 weeks after RYGB or sham surgery. This revealed w1.5-fold higher levels of BAs in GK-RYGB rats (p < 0.05) ( Figure 5A ). As CDCA is one of the major primary bile acids in rodents [24, 25] and in humans [26, 27] , and also the most potent endogenous FXR agonist [19, 27] , we sought to determine whether RYGB also increases CDCA levels. The results indicate that GK-RYGB rats had w1.9-fold higher level of CDCA (p < 0.05) as compared with the sham controls ( Figure 5B ). Since FXR activation leads to suppression of expression of phosphoenolpyruvate carboxykinase (PEPCK), the well-known target gene regulated by FXR [28] , we next examined whether RYGB influences expression of PEPCK. This revealed that PEPCK mRNA level was decreased by w60% (p < 0.05) in GK-RYGB islets as compared with the sham controls (Supplemental Fig. 5 ), confirming FXR activation after RYGB. Given that FXR is responsible for the beneficial effects of BAs in remission of T2D after bariatric surgery [29] , that it mediates the effects of BAs on GSIS in b-cells [18] , and the crucial role of TRPA1 in RYGB-enhanced GSIS ( Figure 3A, B) , we reasoned whether FXR is involved in RYGB-induced increase in TRPA1 expression in b-cells. To Figure 5C , lane 2 vs. 1; Figure 5D , column 2 vs. 1). Whereas, TRPA1 protein abundance in FXR À/--RYGB islets was identical to that in FXR À/--sham controls ( Figure 5C , lane 4 vs. 3; Figure 5D , column 4 vs.
3). These results indicate that RYGB-induced TRPA1 expression requires the participation of FXR.
To further determine whether FXR affects TRPA1 expression in b-cells,
we examined TRPA1 expression in FXR knockdown and overexpressing INS-1 832/13 cells. FXR knockdown led to reduced TRPA1 mRNA ( Figure 6A ) and protein ( Figure 6B ) levels. In agreement, FXR À/-islets had w55% (p < 0.05) and w37% (p ¼ 0.01) lower TRPA1 mRNA and protein levels, respectively, than FXR þ/þ islets ( Figure 6C,   D) . On the other hand, FXR overexpressing INS-1 832/13 cells (Supplemental Fig. 6 ) displayed an increased TRPA1 mRNA ( Figure 6E ) and protein ( Figure 6F ) levels. The same observations were also made in INS-1 832/13 cells chronically treated with either GW4064 ( Figure 6G , H) or CDCA ( Figure 6I ). Finally, we confirmed the FXR-dependent effect of BAs on GSIS. Thus, treatment with GW4064 (Supplemental Fig. 7 ) or CDCA (Supplemental Fig. 8 ) led to a significant increase of GSIS in islets from FXR þ/þ mice, but not in islets from FXR À/-mice, consistent with previous reports [18] .
FXR activation induces direct binding of FXR to the promoter of TRPA1 to promote TRPA1 expression
To get insight into the mechanisms underlying FXR-regulated TRPA1 expression, we surveyed DNA sequence in the TRPA1 locus, which revealed a consensus "AGGTCA" sequence of the FXR binding site (FXRE) in the TRPA1 promoter that is conserved across a varies of species ( Figure 7A ). Chromatin immunoprecipitation (ChIP) assay revealed that stimulation of FXR with GW4064 for 2 h ( Figure 7B ) increased whereas shRNA knockdown of FXR suppressed (Supplemental Fig. 9A ) binding of FXR to the TRPA1 promoter. To investigate whether mutation of the FXR binding site would abolish FXR-induced TRPA1 expression, we constructed a luciferase reporter driven by either the wild-type FXRE or its mutant form "AGGCAG" (Figure 7C ), and transfected them into 293 T cells, followed by GW4064 treatment and detection of the luciferase activity of the reporter gene. We found that GW4064 increased expression of the reporter driven by the wide-type FXRE, but not by the mutant FXRE ( Figure 7D ), demonstrating that FXRE in the TRPA1 promoter is essential for FXR-mediated TRPA1 expression. Our ChIP results also showed that GW4064 increased ( Figure 7E ) whereas FXR knockdown decreased (Supplemental Fig. 9B ) ACH3 marker at the TRPA1 promoter. Since the gene expressing histone acetyltransferase SRC1 is one of the key histone modifiers generating ACH3 [30] , we next determined whether SRC1 mediates ACH3 of TRPA1 promoter in INS-1 832/13 cells. ChIP assay revealed that GW4064 markedly increased ( Figure 7F ) whereas FXR knockdown decreased (Supplemental Fig. 9C ) SRC1 binding to the TRPA1 promoter. To further determine the role of SRC1 in mediating FXR-dependent stimulation of the TRPA1 gene expression, we analyzed TRPA1 expression in INS-1 832/13 cells transfected with a scramble or SRC1 shRNA. We found that SRC1 knockdown abolished the stimulatory effect of GW4064 on TRPA1 expression, albeit the FXR agonist caused a significant increase (p < 0.01) of TRPA1 expression in scramble control cells ( Figure 7G ). These results suggest that FXR activation recruits SRC1 to increase ACH3 markers at the promoter of Figure 7H ). Thus, treatment with GW4064 led to w1.8-fold (p < 0.01) increase of GSIS in control INS-1 832/13 cells, but not in SRC1 knockdown cells. Furthermore, the FXR agonist failed to enhance GSIS in islets from TRPA1 À/À mice ( Figure 7I ), again indicating that stimulatory effect of FXR on GSIS is mediated by TRPA1.
DISCUSSION
In this study, we demonstrate that RYGB restores TRPA1 expression in b-cells from diabetic GK rats, which significantly improves the ability of diabetic b-cells to respond to glucose, thereby enhancing the first phase of GSIS and ameliorating hyperglycemia in GK rats. For the first time to our knowledge, we show that RYGB increases TRPA1 expression via BAs/FXR-mediated increase of ACH3 at the promoter of TRPA1. Our data also revealed that TRPA1 plays a crucial role in glucose-evoked electrical activity and insulin secretion in bcells. Of note, we find that TRPA1 participates in RYGB-improved GSIS and glycemic controls in diabetic GK rats. These findings therefore assign FXR-dependent regulation of TRPA1 a critical role in improvement of b-cell function and glucose homeostasis in diabetes after RYGB surgery. Bile Acids have been implicated as key mediators of the weightindependent effects of bariatric surgery with respect to glucose homeostasis. Our data show that RYGB results in a significant increase of the plasma total bile acid, particularly CDCA in non-obese GK rats ( Figure 5A, B) . Interestingly, this effect of RYGB appears to be more pronounced in high-fat-high-cholesterol diet Wistar rats [31] and obese diabetic Zucker rats [32] . Given that CDCA has the highest affinity for FXR among BA species and the most potent endogenous FXR agonist [19, 27] , elevated CDCA would leads to FXR activation in GK-RYGB rats. In agreement, expression of PEPCK, the target gene that is negatively regulated by FXR activation [28] , was markedly suppressed in GK-RYGB rats (Supplemental Fig. 5 ), again confirming FXR activation by RYGB.
Studies in rodent b-cells and b-cell lines have revealed that BAs potentiates GSIS, an effect dependent on FXR activation [17] . However, the precise molecular mechanism underlying this FXR-mediated effect remains unclear. We now demonstrate that FXR activation leads to increased TRPA1 expression in b-cells, which mediate the stimulatory effect of FXR activation on GSIS. This concept is corroborated by five pieces of evidence. First, there is existence of the FXR binding site (FXRE) at the TRPA1 promoter ( Figure 7A ). Stimulation with FXR agonist GW4064 led to an increase of FXR binding to the TRPA1 promoter ( Figure 7B ). Second, activation of FXR by CDCA or GW4064 increased TRPA1 expression at mRNA ( Figure 6G ) and protein ( Figure 6H, I ) levels. Third, knockdown FXR by shRNA resulted in reduced TRPA1 expression ( Figure 6A, B) . Fourth, TRPA1 expression was substantially decreased in FXR À/-islets ( Figure 6C, D) . Fifth, GW4064 failed to potentiate GSIS in TRPA1 À/À mice, whereas it caused w1.6-fold enhancement in control mice ( Figure 7I ). Importantly, our findings demonstrate that FXR activation promoted the recruitment of the epigenetic regulator SRC1 ( Figure 7F ), and subsequently enhancing histone acetylation at the TRPA1 locus ( Figure 7E ). This would lead to increased expression of TRPA1 gene, given that acetylation of nucleosomal histones increases the accessibility of DNA to transcription factors and leads to increased transcription at the target DNA locus [33] . Consistently, the lack of effect of GW4064 on TRPA1 gene transcription ( Figure 7G ) and GSIS ( Figure 7H ) in shSRC1 cells again indicates that SRC1 is responsible for these effects of FXR. Thus, our results unravel a novel molecular mechanism of regulation of Figure 7J ). Glucose-induced insulin secretion is attributed to the membrane depolarization upon closure of K ATP channels as a result of glucose metabolism and ATP production, which results in activation of voltagedependent Ca 2þ channels and initiation of insulin secretion [8] . Importantly, however, closure of K ATP channels alone is not sufficient to cause membrane depolarization to reach the threshold for regenerative electrical activity (À60 mV) [34] . Hence, b-cells must be equipped with an inward current that may be tonically active, to bring the membrane potential away from the K þ -equilibrium potential. It has been reported previously that activation of TRPA1 results in an increase of cytosolic Ca 2þ and insulin secretion in b-cells [13] . We now confirm and extend these observations. We found that ablation of TRPA1 resulted in decreased glucose-evoked electrical activity ( Figure 4B ) and insulin secretion ( Figure 4C, D) . This observation is further supported by the experiments performed in rat b-cells treated with TRPA1 agonist AITC ( Figure 4E , G) or antagonist HC-030031 ( Figure 4F , H), which resulted in enhanced or suppressed response to glucose. Based on these observations and those published [11, 13] , it is justifiable to conclude that the TRPA1 channel contributes, at least partly, to the background inward current in b-cells. Moreover, our data also suggest that TRPA1 involves in the development of resting membrane potential in b-cells, given that TRPA1-deficient b-cells possessed a more hyperpolarized membrane potential. It is worth noting that, in addition to TRPA1, other TRP members such as TRPM2 may also contribute to the glucoseinduced increase in background current [35] . Nevertheless, our current findings suggest a more prominent role for TRPA1 in b-cell stimulus-secretion coupling.
It is interesting to note that diabetic GK b-cells displayed a marked reduction in TRPA1 expression ( Figure 2 ). This is likely to impair the secretory response to glucose stimulation, given that TRPA1 is required for the ability of glucose to evoke b-cell electrical activity ( Figure 4A , B) and insulin secretion ( Figure 4C, D) . Thus, reduced Original Article TRPA1 expression would account, at least partly, for the diminished GSIS in GK rats ( Figure 1A, B) . Importantly, our data also suggest that restored TRPA1 expression would contribute to improved GSIS after RYGB. Three pieces of evidence corroborate this notion. First, GK-RYGB islets displayed higher TRPA1 expression than GK-sham controls (Figure 2A, B) . Increase in TRPA1 expression was in agreement with a greater TRPA1 agonist-induced current in b-cells from GK-RYGB rats ( Figure 2E ). Second, increased TRPA1 expression is paralleled by improved GSIS in GK-RYGB rats ( Figure 1A, B) . Third, the effect of RYGB on GSIS was significantly attenuated in TRPA1 À/À mice ( Figure 3A, B) . This led to decreased efficacy of RYGB in improving glycemic controls ( Figure 3C ). Collectively, our findings suggest that the BA/FXR/SRC1 axis plays a crucial role in improved GSIS and glycemic control in diabetic GK rats following RYGB ( Figure 7J ). These are important findings as previously little was known as to whether and how BA/FXR signaling can enhance the secretory capacity of b-cells after RYGB, and whether and how alterations in TRPA1 in b-cells would interfere with the ability of glucose to evoke b-cell electrical activity and stimulate insulin secretion, in particular in diabetes. Thus, our studies unravel the BA/ FXR/SRC1 axis-mediated regulation of TRPA1 expression critical for improved GSIS in GK rats after RYGB. It is also worth pointing out that the significance of FXR-dependent regulation of TRPA1 may not only be in non-obese GK rats. It can be speculated that it may also contribute to RYGB-induced improvement of the first phase of insulin secretion in obese diabetes, given the evident effects of RYGB on elevating CDCA and the total BAs [32] , as well as TRPA1 expression (unpublished data) observed in obese Zucker rats. Thus, further exploration of this pathway would help to define novel approaches to treatment of T2D.
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